Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 612

Sort by

Sort Order Select

Journal Articles

A Meta-Analysis Evaluating the Risk of Bleeding-Related Adverse Events with Defibrotide Treatment

William Tappe, Saurabh Aggarwal, Ozlem Topaloglu, Massimo Iacobelli

Blood (2019) 134 (Supplement_1): 2016.

https://doi.org/10.1182/blood-2019-123686

Published: 2019

Journal Articles

A Retrospective Study on Inotuzumab Ozogamicin in Infants and Young Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Erica Brivio, MD, Raoull Hoogendijk, MSc, Christophe Chantrain, MD PhD, Fanny Rialland, MD, Audrey Contet, Sarah Elitzur, MD, Luciano Dalla-Pozza, MBBS FRACP, Krisztian Kallay, MD, Chi Kong Li, MBBS,MD, Motohiro Kato, MD PhD, Inna V Markova, Dr., Kjeld Schmiegelow, Professor MD DMSc., Nicole Bodmer, Rob Pieters, MDPhDMSc, Christian Michel Zwaan, MD PhD

Blood (2019) 134 (Supplement_1): 3890.

https://doi.org/10.1182/blood-2019-126472

Published: 2019

Journal Articles

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse

Blood (2019) 134 (Supplement_1): 3806.

https://doi.org/10.1182/blood-2019-129018

Published: 2019

Journal Articles

A Multisite Phase Ib Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML)

Guru Subramanian Guru Guru Murthy, MBBS, Scott H. Kaufmann, MD PhD, Aniko Szabo, PhD, Arielle Baim, Ashish Anshu, Alexander Hinman, Laura C. Michaelis, MD, Sameem Abedin, MD, Karen-Sue B. Carlson, MD PhD, Lyndsey Runaas, MD, Ehab L. Atallah, MD

Blood (2019) 134 (Supplement_1): 3837.

https://doi.org/10.1182/blood-2019-131728

Published: 2019

Journal Articles

Early Hyperbilirubinemia Is an Independent Predictor of Outcome after Allogeneic Stem Cell Transplantation and Correlates with Markers of Endothelial Cell Dysfunction

Thomas Luft, MD PhD, Hao Dai, Aleksandar Radujkovic, MD, David Schult, Joshua Majer-Lauterbach, Olga Blau, MD PhD, Lars Bullinger, Sihe Jiang, Carsten Müller-Tidow, MD, Peter Dreger, Olaf Penack, MD

Blood (2019) 134 (Supplement_1): 4487.

https://doi.org/10.1182/blood-2019-124284

Published: 2019

Journal Articles

Risk Factors and the Therapeutic Efficacy for Thrombotic Microangiopathy in Patients after Allogeneic Hematopoietic Stem Cell Transplantation - Results of the Multicenter Retrospective Cohort Study

Hiroharu Imoto, Hiroyuki Matsui, MD, Yasuyuki Arai, MD PhD, Tadakazu Kondo, MD PhD, Yasunori Ueda, MD PhD, Kazunori Imada, MD PhD, Takashi Akasaka, MD PhD, Akihito Yonezawa, MD PhD, Kazuhiro Yago, MD PhD, Takayuki Ishikawa, MD PhD, Akifumi Takaori-Kondo, MD PhD

Blood (2019) 134 (Supplement_1): 4554.

https://doi.org/10.1182/blood-2019-123252

Published: 2019

Journal Articles

Allogeneic CD34-Selected HSCT Following CAR T-Cells Is Associated with Low TRM and Favorable OS in Pediatric/Young Adult Patients with Relapsed/Refractory B-ALL

Vanessa Fabrizio, MD, Farid Boulad, MD, Maria I. Cancio, MD, Meghan A. Higman, MD PhD, Steven P. Margossian, MD PhD, Audrey Mauguen, PhD, Susan Prockop, MD, Andromachi Scaradavou, MD, Niketa C. Shah, MD, Barbara Spitzer, MD, Nick Yeager, Nancy A. Kernan, Richard O'Reilly, MD, Jaap Jan Boelens, MD PhD, Kevin J. Curran, MD

Blood (2019) 134 (Supplement_1): 4582.

https://doi.org/10.1182/blood-2019-121767

Published: 2019

Journal Articles

Post Induction and Post Consolidation Measurable/Minimal Residual Disease Predict Relapse in NPM-1 Positive AML. Outcome of Treatment Relapse. a Single Center Experience

Erika Borlenghi, MD, Chiara Pagani, MD, Michele Malagola, MD, Diego Bertoli, PhD, Francesca Schieppati, MD, Silvana Archetti, PhD, Angela Passi, MD, Cinzia Lamorgese, Chiara Cattaneo, MD, Nicola Polverelli, Margherita Sciumé, Rosa Daffini, MD, Doriana Gramegna, MD, Mirella Marini, MD, Giuseppe Rossi

Blood (2019) 134 (Supplement_1): 2695.

https://doi.org/10.1182/blood-2019-126074

Published: 2019

Journal Articles

A Phase I Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Preliminary Results of the ITCC-059 Study

Blood (2019) 134 (Supplement_1): 2629.

https://doi.org/10.1182/blood-2019-122411

Published: 2019

Journal Articles

Validation of Recently Proposed Risk and Prognostic Factors for Thrombotic Microangiopathy after Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Gi June Min, MD, Hee-Je Kim, MD PhD, Sung-Soo Park, MD, Silvia Park, Young-Woo Jeon, MD PhD, Seung-Ah Yahng, MD PhD, Seung-Hwan Shin, MD PhD, Jae-Ho Yoon, MD PhD, Sung-Eun Lee, MD, Byung Sik Cho, MD PhD, Ki-Seong Eom, MD PhD, Yoo-Jin Kim, MD PhD, Seok Lee, MD PhD, Chang-Ki Min, MD PhD, Seok-Goo Cho, MD PhD, Dong-Wook Kim, Jong-Wook Lee, MD PhD

Blood (2019) 134 (Supplement_1): 3260.

https://doi.org/10.1182/blood-2019-124275

Published: 2019

Journal Articles

Study Design of an Open-Label, Single-Arm, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Defibrotide in Adult Patients with Transplant-Associated Thrombotic Microangiopathy

Vincent T. Ho, Nino Keshelava, Suzanne Swann, William Tappe

Blood (2019) 134 (Supplement_1): 3257.

https://doi.org/10.1182/blood-2019-123520

Published: 2019

Journal Articles

Fludarabine and Cyclophosphamide Based Conditioning Is Associated with Good Outcomes in Patients Undergoing Matched Sibling Donor Transplants for Aplastic Anaemia

Biju George, MDDM, Aby Abraham, MD DM, Anu Korula, MD DM, Anup Devasia, MD DM, Kavitha M Lakshmi, MSc, Uday Prakash Kulkarni, MD DM, Fouzia N Abu Backer, MD DM, Alok Srivastava, MD,FRACP,FRCPA, Vikram Mathews, MD DM

Blood (2019) 134 (Supplement_1): 3272.

https://doi.org/10.1182/blood-2019-129328

Published: 2019

Journal Articles

Incidence, Risk Factors and Outcomes of Veno-Occlusive Disease / Sinusoidal Obstruction Syndrome (VOD/SOS) in Children with Severe Thalassemia (ST) Conditioned with Busulfan- Cyclophosphamide (Bu-Cy) Based Regimen

Stalin Ramprakash, MD MBBS, Rajat Kumar Agarwal, BS, C P Raghuram, MD, Pallavi Mehta, Deepa Trivedi, MD, Priya Marwah, Rajpreet Soni, Rakesh Dhanya, BE, Lawrence Faulkner, MD

Blood (2019) 134 (Supplement_1): 4499.

https://doi.org/10.1182/blood-2019-130841

Published: 2019

Journal Articles

Outcomes of Total Body Irradiation- Versus Chemotherapy-Based Myeloablative Conditioning Regimen in Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide for Acute Myelogenous Leukemia: ALWP of the EBMT Study

Bhagirathbhai Dholaria, MBBS, Myriam Labopin, MD, Emanuele Angelucci, MD, Fabio Ciceri, MD, José Luis Díez-Martín, MD PhD, Benedetto Bruno, MD, Simona Sica, MD, Yener Koc, MD, Zafer Gulbas, MD, Christoph Schmid, MD, Didier Blaise, MD PhD, Angelo Michele Carella, Giuseppe Visani, Bipin N. Savani, MD, Arnon Nagler, MD MSc, Mohamad Mohty, MD PhD

Blood (2019) 134 (Supplement_1): 4584.

https://doi.org/10.1182/blood-2019-122279

Published: 2019

Journal Articles

Adjusting BuCy 2 in Allogeneic Hematopoietic Stem Cell Transplantation to Improve Outcomes: Experience of a Limited-Resource Center in a Developing Country

Monica Magdalena Rivera Franco, MDMSc, Eucario Leon Rodriguez, MD

Blood (2019) 134 (Supplement_1): 4480.

https://doi.org/10.1182/blood-2019-122203

Published: 2019

Journal Articles

Underdiagnosed Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome(VOD/SOS) As a Major Cause of Multi-Organ Failure in Acute Leukemia Transplant Patients: An Analysis from the EBMT Acute Leukemia Working Party

Blood (2019) 134 (Supplement_1): 4483.

https://doi.org/10.1182/blood-2019-124065

Published: 2019

Journal Articles

Phase I Study of Pracinostat in Combination with Gemtuzumab Ozogamicin (PraGO) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Talha Badar, MD, Guru Subramanian Guru Murthy, MD, Lyndsey Runaas, MD, Karen-Sue B. Carlson, MD PhD, Laura C. Michaelis, MD, Alexandra M. Harrington, MDMT(ASCP), Ehab L. Atallah, MD, Sameem Abedin, MD

Blood (2019) 134 (Supplement_1): 5068.

https://doi.org/10.1182/blood-2019-123237

Published: 2019

Journal Articles

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Naval G. Daver, MD, Pau Montesinos, MD PhD, Daniel J. DeAngelo, MD, Eunice S. Wang, MD, Nikolaos Papadantonakis, MDPhDMSc, Eric Deconinck, MD PhD, Harry P. Erba, MD PhD, Naveen Pemmaraju, MD, Andrew A. Lane, MD PhD, David A. Rizzieri, MD, Kendra L. Sweet, MD, Giovanni Martinelli, Corrado Tarella, MD, Elisabetta Todisco, MD PhD, Marina Y Konopleva, MD PhD, Callum M. Sloss, PhD, Kerry Culm-Merdek, PhD, Patrick A. Zweidler-McKay, MD PhD, Hagop M. Kantarjian, MD

Blood (2019) 134 (Supplement_1): 734.

https://doi.org/10.1182/blood-2019-128648

Published: 2019

Journal Articles

Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Blood (2019) 134 (Supplement_1): 823.

https://doi.org/10.1182/blood-2019-125136

Published: 2019

Journal Articles

Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML

Blood (2019) 134 (Supplement_1): 831.

https://doi.org/10.1182/blood-2019-126065

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A Meta-Analysis Evaluating the Risk of Bleeding-Related Adverse Events with Defibrotide Treatment

A Retrospective Study on Inotuzumab Ozogamicin in Infants and Young Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse

A Multisite Phase Ib Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML)

Early Hyperbilirubinemia Is an Independent Predictor of Outcome after Allogeneic Stem Cell Transplantation and Correlates with Markers of Endothelial Cell Dysfunction

Risk Factors and the Therapeutic Efficacy for Thrombotic Microangiopathy in Patients after Allogeneic Hematopoietic Stem Cell Transplantation - Results of the Multicenter Retrospective Cohort Study

Allogeneic CD34-Selected HSCT Following CAR T-Cells Is Associated with Low TRM and Favorable OS in Pediatric/Young Adult Patients with Relapsed/Refractory B-ALL

Post Induction and Post Consolidation Measurable/Minimal Residual Disease Predict Relapse in NPM-1 Positive AML. Outcome of Treatment Relapse. a Single Center Experience

A Phase I Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Preliminary Results of the ITCC-059 Study

Validation of Recently Proposed Risk and Prognostic Factors for Thrombotic Microangiopathy after Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Study Design of an Open-Label, Single-Arm, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Defibrotide in Adult Patients with Transplant-Associated Thrombotic Microangiopathy

Fludarabine and Cyclophosphamide Based Conditioning Is Associated with Good Outcomes in Patients Undergoing Matched Sibling Donor Transplants for Aplastic Anaemia

Incidence, Risk Factors and Outcomes of Veno-Occlusive Disease / Sinusoidal Obstruction Syndrome (VOD/SOS) in Children with Severe Thalassemia (ST) Conditioned with Busulfan- Cyclophosphamide (Bu-Cy) Based Regimen

Outcomes of Total Body Irradiation- Versus Chemotherapy-Based Myeloablative Conditioning Regimen in Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide for Acute Myelogenous Leukemia: ALWP of the EBMT Study

Adjusting BuCy 2 in Allogeneic Hematopoietic Stem Cell Transplantation to Improve Outcomes: Experience of a Limited-Resource Center in a Developing Country

Underdiagnosed Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome(VOD/SOS) As a Major Cause of Multi-Organ Failure in Acute Leukemia Transplant Patients: An Analysis from the EBMT Acute Leukemia Working Party

Phase I Study of Pracinostat in Combination with Gemtuzumab Ozogamicin (PraGO) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only